Enter inventor name

Mitchell E Reff

This inventor holds 25 USPTO granted patents and 1 published patent application, primarily in Monoclonal Antibodies. Top assignees: Idec Pharmaceuticals Corporation, Biogen Idec, Inc., Biogen Idec Ma Inc.. Active years: 1997-2013.

USPTO Granted Patents = 25 (Patent Applications = 1)

% Patents Active = 64.0

Average Co-Inventor Count = 2.6

ph-index = 15

Forward Citations = 1,804(Granted Patents)

Company Filing History:

9 out of 37

Idec Pharmaceuticals Corporation

Idec Pharmaceutical Corporation

patents

5. 1 out of 3,798

Johns Hopkins University

patents

6. 1 out of 195

Seikagaku Corporation

patents

7. 1 out of 834,453

Other

patents

where one patent can have more than one assignee

Years Active: 1997-2013

Loading Chart...

Areas of Expertise:

Monoclonal Antibodies

Anti-CD20

Anti-CD4

Therapeutics

Chimeric Antibodies

B Cell Lymphoma

Recombinant Antibodies

Peptides

Apoptosis Inhibition

Gene Integration

Selectable Marker

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8603473 - Modified binding molecules comprising connecting peptides (2013-12-10),

2. 7744877 - Expression and use of anti-CD20 Antibodies (2010-06-29),

3. 7695940 - Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics (2010-04-13),

4. 7604989 - Inhibition of apoptosis process and improvement of cell performance (2009-10-20),

5. 7452534 - Recombinant anti-CD4 antibodies for human therapy (2008-11-18),

6. 7438906 - Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics (2008-10-21),

7. 7422739 - Anti-CD20 antibodies (2008-09-09),

8. 7381560 - Expression and use of anti-CD20 antibodies (2008-06-03),

9. 7338658 - Recombinant anti-CD4 antibodies for human therapy (2008-03-04),

10. 7332163 - Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics (2008-02-19),

11. 7223392 - Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics (2007-05-29),

12. 7033589 - γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics (2006-04-25),

13. 6893636 - Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics (2005-05-17),

14. 6682734 - Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma (2004-01-27),

15. 6399061 - Chimeric and radiolabelled antibodies specific to human CD20 antigen and use thereof for treatment of B-cell lymphoma (2002-06-04),

Title: Inventor Mitchell E Reff - Revolutionizing Technology in San Diego

Introduction: Mitchell E Reff is a distinguished inventor based in San Diego, CA, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Mitchell E Reff holds several patents in the areas of artificial intelligence, renewable energy, and biotechnology, showcasing his versatility and forward-thinking approach to invention.

Career Highlights: With a career spanning over two decades, Mitchell E Reff has worked with leading tech companies, research institutions, and universities to develop cutting-edge solutions that have had a significant impact on various industries.

Collaborations: Throughout his career, Mitchell E Reff has collaborated with top scientists, engineers, and inventors, fostering a culture of innovation and excellence in all his projects. His collaborative spirit has led to the creation of groundbreaking technologies that have shaped the future of multiple sectors.

Conclusion: Mitchell E Reff's passion for innovation, coupled with his dedication to pushing the boundaries of technology, has solidified his reputation as a visionary inventor in San Diego and beyond. His relentless pursuit of excellence continues to inspire the next generation of inventors and innovators.

Profile summary based on public USPTO records.

Please report any incorrect information to [email protected]